Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this document? Why not share!

Alzheimer Disease Report Cbdmt 1 June 2010 Global Report Toc

on

  • 851 views

According to CBDMT, the market and business intelligence company, the Alzheimer\'s disease (AD) market was valued at $5.5 billion in 2009. The AD market is led by North America with a market share of ...

According to CBDMT, the market and business intelligence company, the Alzheimer\'s disease (AD) market was valued at $5.5 billion in 2009. The AD market is led by North America with a market share of 52% accounting for sales of $2.8 billion. The Alzheimer disease market could account for more than $10.1 billion by 2020.

Statistics

Views

Total Views
851
Views on SlideShare
842
Embed Views
9

Actions

Likes
0
Downloads
8
Comments
0

1 Embed 9

http://www.linkedin.com 9

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Alzheimer Disease Report Cbdmt   1 June 2010   Global Report Toc Alzheimer Disease Report Cbdmt 1 June 2010 Global Report Toc Document Transcript

  • Alzheimer’s Disease (AD) ReportAuthors: Emilie Hilpert, Philippe TramoyDate: 01 June 2010“Copyright 2010 CBDMT SARL. All rights reserved. Any unauthorized use or disclosure is prohibited. The information hereinwas obtained from various sources; we do not guarantee its accuracy or completeness. This research report is prepared forgeneral circulation and is circulated for general information only. It does not have regard to specific investment objectives,financial situation and the particular needs of any particular person who may receive this report. Investors should seekfinancial advice regarding the appropriateness of investing in any securities or investment and trading strategies discussedor recommended in this report and should understand that the statements regarding future prospects may not be realized.Investors should note that income from such securities, if any, may fluctuate and that each securitys price or value may riseor fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide tofuture performance. Neither the information nor any opinion expressed constitutes an offer to buy or sell any securities oroptions or futures contracts. CBDMT SARL accepts no responsibility or liability whatsoever for any expense, loss or damagesarising out of or in any way connected with the use of all or any part of this report. CBDMT SARL does not have long or shortposition in any securities or options of this issue(s)."CBDMT – Market & Business Intelligence © 2010 www.cbdmt.com
  • Table of Contents1 Global information .......................................................................................................................... 5 1.1 History ..................................................................................................................................... 5 1.2 Presentation of the disease ..................................................................................................... 5 1.3 Patients with Alzheimer’s disease forecast ............................................................................. 5 1.4 Prevalence ............................................................................................................................... 72 Alzheimer’s disease ......................................................................................................................... 7 2.1 Symptoms ................................................................................................................................ 7 2.2 Physiopathology ...................................................................................................................... 9 2.3 Risk factors ............................................................................................................................ 12 Age ................................................................................................................................................. 12 Sex ................................................................................................................................................. 12 Genetic affects............................................................................................................................... 12 2.4 Alzheimer’s disease as a genetic disease .............................................................................. 13 2.5 Diagnosis................................................................................................................................ 133 Market ........................................................................................................................................... 15 3.1 Overview................................................................................................................................ 15 3.2 Treatments and products ...................................................................................................... 16 Acetylcholinesterase inhibitors ..................................................................................................... 21 NMDA receptor antagonist ........................................................................................................... 23 3.3 Market previsions .................................................................................................................. 234 Products in development .............................................................................................................. 25 4.1 Overview................................................................................................................................ 25 4.2 Products in phase III .............................................................................................................. 26 Bapineuzumab ............................................................................................................................... 28 Dimebon ........................................................................................................................................ 30 EGb-761 ......................................................................................................................................... 35 Immune Globulin Intravenous....................................................................................................... 36 Leuprolide acetate implant ........................................................................................................... 37CBDMT – Market & Business Intelligence © 2010 www.cbdmt.com 2/70
  • LY-450139 ...................................................................................................................................... 38 Neramexane .................................................................................................................................. 39 4.3 Products in phase II ............................................................................................................... 405 Pipeline of drugs for Alzheimer’s disease, Discovery to Phase II .................................................. 42 5.1 Drugs in phase II .................................................................................................................... 42 5.2 Drugs in phase I ..................................................................................................................... 45 5.3 Drugs in preclinical phase ...................................................................................................... 48 5.4 Drugs in discovery phase ....................................................................................................... 506 Company profiles .......................................................................................................................... 55 6.1 Baxter International Inc ......................................................................................................... 55 6.2 Bellus Health Inc .................................................................................................................... 57 6.3 Eisai Co Ltd............................................................................................................................. 58 6.4 Elan Corp Plc .......................................................................................................................... 59 6.5 Eli Lilly and Co ........................................................................................................................ 61 6.6 Forest laboratories Inc........................................................................................................... 63 6.7 Johnson & Johnson ................................................................................................................ 64 6.8 Merz pharmaceutical............................................................................................................. 66 6.9 Novartis Ag ............................................................................................................................ 67 6.10 Pfizer Inc ................................................................................................................................ 69List of FiguresFigure 1: Estimated evolution of people with Alzheimer’s disease 2010 to 2050 (in millions) bygeographical zones .................................................................................................................................. 6Figure 2: Progression of Alzheimers disease (black dots) ...................................................................... 9Figure 3: Diagram of physiopathology mechanisms ............................................................................. 11Figure 4: Sales repartition by types of drugs ......................................................................................... 15Figure 5: Sales repartition by geographical zones ................................................................................. 15Figure 6: Sales repartition by pharmaceutical companies .................................................................... 16Figure 7: Therapeutic ways to treat Alzheimers disease ...................................................................... 17Figure 8: Sales of marketed drugs by therapeutic classes .................................................................... 19Figure 9: Sales distribution of Aricept in 2009 ...................................................................................... 22Figure 10: Estimated evolution of sales for Alzheimers disease drugs for 2009 to 2020 .................... 23Figure 11: Repartion of Alzheimers drugs turnover for 2009 to 2020 ................................................. 24CBDMT – Market & Business Intelligence © 2010 www.cbdmt.com 3/70
  • Figure 12: Pipeline drugs in development in 2010 ................................................................................ 25Figure 13: Clinical trials by development phases .................................................................................. 26Figure 14: Drugs in phase III by therapeutic classes.............................................................................. 26Figure 15: Drugs in phase II by therapeutic classes............................................................................... 40Figure 16: Repartition of symptomatic treatments by mechanisms of action ..................................... 41Figure 17: Repartition of curative treatments by mechanisms of action ............................................. 41List of TablesTable 1: Total population over 65, estimated number of people with Alzheimer’s disease from 2010to 2020 (in millions) by geographical zones ............................................................................................ 6Table 2: Incidence and prevalence on population aged 65 and over in 2010, 2015 and 2020 bygeographical zones .................................................................................................................................. 7Table 3: Main warning signs of Alzheimers disease ............................................................................... 7Table 4: Common clinical features in Alzheimer’s disease ..................................................................... 8Table 5: Potential risks and protective factors for Alzheimer’s disease ............................................... 12Table 6: Differences between genetic disease and genetic susceptibility4........................................... 13Table 7: Main brand-name drugs sold in the world .............................................................................. 18Table 8: Alzheimers degree of severity treated by marketed drugs .................................................... 19Table 9: Current drug treatments for Alzheimers disease ................................................................... 20Table 10: Sales and forecast of main acetylcholinesterase inhibitor drugs .......................................... 21Table 11: Sales and forecast of main NMDA receptor antagonist drugs .............................................. 23Table 12: Drugs in phase III ................................................................................................................... 26Table 13: Alzheimers degree of severity treated by drugs in phase III ................................................ 27Table 14: Clinical trials of Bapineuzumab ............................................................................................. 29Table 15: Clinical trials of Dimebon ....................................................................................................... 32Table 16: Clinical trials of EGb-761 ........................................................................................................ 35Table 17: Clinical trials of Gammagard (Immune Globulin Intravenous) .............................................. 36Table 18: Clinical trials of Memryte (leuprolide acetate implant) ........................................................ 37Table 19: Clinical trials of LY-450139..................................................................................................... 38Table 20: Clinical trials of Neramexane ................................................................................................. 40CBDMT – Market & Business Intelligence © 2010 www.cbdmt.com 4/70
  • 1 Global informationAlzheimer’s disease is a neurological disorder affecting the central nervous system (CNS) that leads toa progressive loss of memory, language, and the ability to recognize friends and family. The averagecourse of the disease, from early symptoms to complete loss of cognitive ability, is 10 years. 1.1 HistoryIn 1906, at a psychiatry meeting, the German psychiatrist Alois Alzheimer (1864-1915) presented theAuguste’s case, a patient whom he examined a few years before. Auguste D. was a 51-year-oldwoman, who was suffering from disorientation, aphasia, auditory hallucinations, paranoia,unpredictable behavior and pronounced psycho-social impairment. Alois Alzheimer describedorganic changes in her brain, like plaques, tangles and arteriosclerosis. This finding formed hishypothesis of her dementia having an organic cause. Even if History has retained Alzheimer’s namefor talking about this kind of dementia, his description was not a new discovery. The associationbetween plaques and dementia had been reported in 1887 for the first time by S. Beljahow. 1.2 Presentation of the diseaseAlzheimer’s disease (AD) is by far the most common cause of dementia1 associated with aging; itaccounts for more than 60% of all dementia. Alzheimer’s disease is characterized by an insidiousonset and slow deterioration in cognition, functional ability (e.g., activities of daily living), behavior,and mood. In USA, AD is the 7th leading cause of mortality.In 2010, more of 21 million people will be affected by this disease in the world. As the worldpopulation ages, this number will increase. 1.3 Patients with Alzheimer’s disease forecastToday, more than 20.8 million people are affected by Alzheimer’s disease around the world. TheAlzheimer’s disease patient population will grow over the next 10 years. As the ‘baby boomer’generation ages in developed countries, the percentage of the population aged 65 and over willincrease to reach 716.4 million by 2020. The Alzheimer’s disease patient population is forecast to beup to 31.3 million by 2020. Estimations predict nearly a doubling of patients every 20 years.The Alzheimer’s disease population in Asia is projected to grow at the highest rate to reach 15 millionaccounting for nearly half of AD patients by 2020.1 Dementia is a syndrome due to disease of the brain, usually chronic, characterized by a progressive, global deterioration inintellect including memory, learning, orientation, language, comprehension and judgment.CBDMT – Market & Business Intelligence © 2010 www.cbdmt.com 5/70